Reducing Risk for Thrombosis in Patients With Lung Cancer

Researchers have examined whether treatment with lazertinib-amivantamab entails an increased risk of venous thromboembolism in patients with advanced or metastatic non–small cell lung cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/993428?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?